ANL 28.17 Decreased By ▼ -0.63 (-2.19%)
ASC 16.76 Increased By ▲ 0.28 (1.7%)
ASL 23.95 Increased By ▲ 0.46 (1.96%)
AVN 91.66 Decreased By ▼ -0.16 (-0.17%)
BOP 9.71 Decreased By ▼ -0.11 (-1.12%)
BYCO 9.93 Decreased By ▼ -0.28 (-2.74%)
DGKC 113.50 Decreased By ▼ -0.70 (-0.61%)
EPCL 48.84 Decreased By ▼ -0.77 (-1.55%)
FCCL 21.66 Increased By ▲ 0.31 (1.45%)
FFBL 27.70 Increased By ▲ 1.21 (4.57%)
FFL 17.99 Decreased By ▼ -0.30 (-1.64%)
HASCOL 14.82 Decreased By ▼ -0.16 (-1.07%)
HUBC 86.45 Increased By ▲ 1.05 (1.23%)
HUMNL 7.35 Increased By ▲ 0.02 (0.27%)
JSCL 29.60 Decreased By ▼ -0.25 (-0.84%)
KAPCO 38.31 Decreased By ▼ -0.19 (-0.49%)
KEL 4.24 Decreased By ▼ -0.06 (-1.4%)
LOTCHEM 15.96 Decreased By ▼ -0.27 (-1.66%)
MLCF 43.55 Decreased By ▼ -0.52 (-1.18%)
PAEL 40.60 Decreased By ▼ -0.50 (-1.22%)
PIBTL 13.00 Decreased By ▼ -0.12 (-0.91%)
POWER 11.78 Increased By ▲ 0.67 (6.03%)
PPL 97.45 Decreased By ▼ -0.65 (-0.66%)
PRL 25.48 Decreased By ▼ -0.32 (-1.24%)
PTC 9.78 Decreased By ▼ -0.13 (-1.31%)
SILK 1.21 Decreased By ▼ -0.02 (-1.63%)
SNGP 46.49 Decreased By ▼ -0.30 (-0.64%)
TRG 97.38 Increased By ▲ 2.18 (2.29%)
UNITY 31.58 Decreased By ▼ -0.62 (-1.93%)
WTL 1.18 No Change ▼ 0.00 (0%)
BR100 4,856 Decreased By ▼ -11.74 (-0.24%)
BR30 24,507 Decreased By ▼ -1.43 (-0.01%)
KSE100 45,931 Decreased By ▼ -58.35 (-0.13%)
KSE30 19,110 Decreased By ▼ -68.04 (-0.35%)

Moderna will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).

“Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,” he was quoted as saying.

On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.

“Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks,” Bancel told WamS, adding it was just a “matter of days” until a contract would be ready.

Moderna has said its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial, becoming the second developer to report results that far exceeded expectations after Pfizer and its partner BioNTech.

The EU has been in talks with Moderna for its experimental COVID-19 vaccine at least since July.